← FDA DRUG APPROVALS

FDA ANDA · ANDA076753

BETAMETHASONE DIPROPIONATE

Sponsor: SUN PHARMA CANADA

APPLICATION
ANDA076753
TYPE
ANDA
ORIGINAL APPROVAL
2004-10-12
LATEST ACTION
2020-06-11
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT, AUGMENTED
MARKETING STATUS
Discontinued

Products

BETAMETHASONE DIPROPIONATEDiscontinued
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE · OINTMENT, AUGMENTED · TOPICAL

Approval history

2020-06-11Labeling · Supplement 9 · standardAP
2015-06-04Labeling · Supplement 7 · standardAP
2004-10-12OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →